多重单细胞分析FNA可准确诊断唾液腺肿瘤
研究开发了FAST多重循环单细胞分析技术,用29种蛋白标记物对细针穿刺(FNA)样本进行检测。在151,926个细胞训练集和30例验证队列中,该技术区分良恶性唾液腺肿瘤的准确率在FNA样本为0.88,多标记物优于单标记物,并可评估NTRK表达。
要点
- FAST技术可从FNA单细胞样本快速检测29种蛋白标记物。
- FNA样本良恶性鉴别准确率达0.88,多标记物优于单标记物。
- 该技术可同步评估NTRK等治疗相关生物标志物。
核心结论
- 新型多重单细胞FAST技术可从FNA样本快速、低成本地进行生物标志物检测,辅助唾液腺肿瘤良恶性诊断。
研究设计与样本
- 开发FAST多重循环单细胞成像技术,验证29种蛋白标记物,用151,926个细胞(N=26原发唾液腺肿瘤)训练预测模型,并在独立队列(N=30)验证。
主要发现
- FAST区分良恶性唾液腺肿瘤的准确率在单细胞匀浆样本为0.86,在FNA样本为0.88。
- 多标记物联合检测的准确率为0.82,高于单标记物的0.65-0.74,且不依赖采样细胞数。
- FAST可评估NTRK表达,提示该技术的治疗应用潜力。
关键数值与推荐
- FAST诊断良恶性唾液腺肿瘤准确率:单细胞匀浆样本0.86,FNA样本0.88。
- 多标记物与单标记物诊断准确率分别为0.82与0.65-0.74。
临床怎么用
- FAST-FNA方法可模块化定制,适用于细胞学样本稀缺或不确定的多种病理和器官系统,改善诊断流程并支持及时治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing salivary gland tumors (SGTs) through fine-needle aspiration (FNA) biopsies is challenging due to the overlapping cytomorphologic features between benign and malignant tumors. The authors developed an innovative, multiplexed cycling technology for the rapid analyses of single cells obtained from FNA that can facilitate the molecular analyses and diagnosis of SGTs. Antibodies against 29 protein markers associated with 7 SGT subtypes were validated and chemically modified via custom linker-bio-orthogonal probes (FAST). Single-cell homogenates and FNA samples were profiled by FAST cyclic imaging and computational analysis. A prediction model was generated using a training set of 151,926 cells from primary SGTs (N = 26) and validated on a separate cohort (N = 30). Companion biomarker testing, such as neurotrophic tyrosine receptor kinase (NTRK), was also assessed with the FAST technology. The FAST molecular diagnostic assay was able to distinguish between benign and malignant SGTs with an accuracy of 0.86 for single-cell homogenate samples and 0.88 for FNA samples. Profiling of multiple markers as compared to a single marker increased the diagnostic accuracy (0.82 as compared to 0.65-0.74, respectively), independent of the cell number sampled. NTRK expression was also assessed by the FAST assay, highlighting the potential therapeutic application of this technology. Application of the novel multiplexed single-cell technology facilitates rapid biomarker testing from FNA samples at low cost. The customizable and modular FAST-FNA approach has relevance to multiple pathologies and organ systems where cytologic samples are often scarce and/or indeterminate resulting in improved diagnostic workflows and timely therapeutic clinical decision-making.
引用
- Oh J, Yoo TY, Saal TM, et al. Multiplexed single-cell analysis of FNA allows accurate diagnosis of salivary gland tumors. Cancer Cytopathol. 2022. PMID: 35666645. doi:10.1002/cncy.22594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。